asthma
Conditions
Interventions
treatment group:Salmeterol ticasone
Sponsors
the second affiliated hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Patients with asthma who met the diagnostic criteria set by asthma Group of Respiratory Society of Chinese Medical Association in 2020; (2) Age 18-70, regardless of gender; (3) Positive bronchial dilation test, that is, FEV1 increased by >= 12% after inhaling bronchial dilation agent(salbutamol), and the absolute value of FEV1 increased by >= 200ml. Or diurnal variation of maximum expiratory peak flow rate (PEF) >= 20% on at least one day in the past 7 days; (4) No serious heart, liver, kidney or other systemic diseases; (5) Agree to participate in this study and sign written informed consent.
Exclusion criteria
Exclusion criteria: (1) Occupational asthma or asthma associated with aspirin or non-steroidal anti-inflammatory drugs; (2) Recent use of drugs that may cause bronchospasm or affect lung function; (3) Malignant tumors of any organ system with serious diseases of heart, liver, kidney, lung, digestive tract, endocrine and blood system, etc., treated or untreated; (4) Have a history of other lung active diseases besides asthma (such as chronic bronchitis, chronic obstructive pulmonary disease, allergic granulomatous vasculitis, allergic bronchopulmonary aspergillosis); (5) Smokers who had smoked for 1 year prior to the trial or who had smoked for an average of >20 years and had quit smoking for 12 months prior to the trial; (6) Have a history of alcohol and drug abuse; (7) Pregnant and lactating women; (8) Mental abnormalities; (9) Other patients considered unsuitable for the study by the clinician. The patient's apparent illness prompted researchers to think that the patient might be at risk or might influence the outcome of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute attack rate in asthmatic patients after 24 weeks of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of FEV1 after 24 weeks of treatment;ACT changes after 24 weeks of treatment;The amount of FENO changed after 24 weeks of treatment; | — |
Countries
China
Contacts
Public ContactQiufen Xun
Outcome results
None listed